Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Rucaparib (AG-014699,PF-01367338)
Cat No.
CEI-0327
Description
Rucaparib (AG-014699, PF-01367338) can inhibit PARP with IC50 of 1.4 nM.
Alias
AG-014447
CAS No.
459868-92-9
Molecular Weight
421.36
Purity
>99%
Storage
2 years at -20centigrade Powder
Synonyms
AG-014447
Targets
PARP
Molecular Formula
C19H18FN3O.H3PO4
Chemical Name
8-fluoro-5-(4-((methylamino)methyl)phenyl)-3,4-dihydro-2H-azepino[5,4,3-cd]indol-1(6H)-one phosphoric acid
Solubility
DMSO 84 mg/mL Water
In vitro
Rucaparib (AG-014699, PF-01367338) is a potent inhibitor of purified full-length human PARP-1. AG-014699, at concentrations of 0.1, 0.4 and 1 mM, inhibited PARP-1 activity by 81.1, 96.8 and 97.1%, respectively. At the concentration of 0.4 mM, AG-014699 caused almost total inhibition of the PARP activity in medulloblastoma cells. AG014699, at the concentration less than 10 uM, was cytotoxic to cells with mutated BRCA1/2 or XRCC3 and to UACC3199 cells with epigenetically silenced BRCA1. AG014699 induced DNA double-strand breaks in all nine cell lines studied. HRR was observed only in cells with functional BRCA1/2 proteins.
In vivo
(1)Combination of AG-014699 and temozolomide can produce a increase in temozolomide-induced tumour growth delay in D384Med xenografts. Consistent with the in vitro data, temozolomide caused complete tumour regressions of D425Med xenografts, whereas D283Med xenografts were relatively resistant. AG-014699 was not toxic, accumulated and reduced PARP activity with more than 75% in xenograft and brain tissues. (2) Combination of AG-014699 and carboplatin can reduce growth of xenograft tumors with BRCA1/2 mutations or with epigenetically silenced BRCA1.
Download
Download Datasheet